Xanamen Clinical Development & Investor Update
Filed with ASX · · 33 pages · English
Sydney, 26 June 2019. Actinogen Medical (ASX: ACW, ‘ACW’ or ‘the Company’) is pleased to provide an update on the progress the Company is making with the ongoing clinical development program for Xanamem™. This update should be read in conjunction with the latest investor presentation (attached). XanADu Phase II Clinical Trial • The Company has made good progress in performing deeper analyses of th
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- XanaHES Trial to Continue
- Phase II Alzheimers Disease Trial - results
- March 2019 Quarterly Update
- New Clinical Development Opportunities for Xanamem
- DSMB again reaffirms XanADu trial to continue without change
Later from Actinogen Medical
- June 2019 Quarterly Update
- Cognitive improvement demonstrated with Xanamem
- September 2019 Quarterly Update
- R&D Tax Incentive rebate received of $4.58 million
- ACW 2019 AGM Chairman's Address
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical